ESR1 and endometrial cancer: For example, Varol Gülseren recently proposed to use the combined ratio of the two groups of the immunohistochemical markers ([P53 + Ki67]/[ER + PR]) to predict the lymph node metastasis of endometrial cancer (11); Louis J.M. suggested that adding estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to the histology-based endometrial cancer recurrence prediction models (7).